Latest OptiNose US Inc. Stories

2014-01-30 08:32:21

AVP-825 uses novel Breath Powered(TM) drug delivery to treat migraine YARDLEY, Pa., Jan. 30, 2014 /PRNewswire/ -- A New Drug Application (NDA) was submitted on Monday January 27, 2014 to the U.S. Food and Drug Administration for AVP-825, a product using OptiNose's innovative closed-palate Breath Powered intranasal delivery system to deliver low-dose sumatriptan powder for the acute treatment of migraine. The NDA submission is based on a series of laboratory and clinical studies...

Word of the Day
  • The prevailing range of a vocal or instrumental part, within which most of the tones lie.
This word is Italian in origin and comes from the Latin 'textura,' web, structure.